KRas mutations and elevated KRas expression, as mentioned previously, are associated with driving forward metabolic activity associated with tumors (such as increased reliance on glucose, increased energy needs, increased TCA cycle activity, etc.)and previous research has shown similarities in metabolic activities between lung adenocarcinoma mouse models and human NSCLC tumor cells [261,262]. This evidence concerns the gene KRAS and non-small cell lung carcinoma.